FindTrial
Sign In

Comparison of Holmium Laser Enucleation of the Prostate (HoLEP) versus MOSESTM Laser Enucleation of the Prostate (MoLEP) in Benign Prostate Syndrome (BPS) - a prospective randomized non-inferiority study

Comparison of Holmium Laser Enucleation of the Prostate (HoLEP) versus MOSESTM Laser Enucleation of the Prostate (MoLEP) in Benign Prostate Syndrome (BPS) - a prospective randomized non-inferiority study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00030642
Enrollment
152
Registered
2023-01-03
Start date
2024-08-01
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

N40

Interventions

Group 1: Patients receive the classic HoLEP as a surgical procedure. Group 2: The patients receive the new MoLEP as a surgical procedure.

Sponsors

Universitätsklinikum Frankfurt Klinik für Urologie
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Indication for subvesical deobstruction

Exclusion criteria

Exclusion criteria: Prostate less than or equal to 30ccm, urethral stricture, punch biopsy confirmed carcinoma of the prostate, preoperative evidence of prostate carcinoma, neurogenic bladder emptying disorder

Design outcomes

Primary

MeasureTime frame
postoperative difference in micturition symptoms, which will be collected using the International Prostate Symptom Score (IPSS) questionnaire at inclusion in the study and 3, 6 and 12 months postoperatively—

Secondary

MeasureTime frame
Complications, uroflow (Qmax), residual urine, operating times, catheter time, hospital length of stay and sexual/ejaculatory function—

Countries

Germany

Contacts

Public ContactMarina Kosiba

Universitätsklinikum Frankfurt Klinik für Urologie

kosiba.marina@kgu.de069 6301-5865

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026